UBS Group’s Translational Development Acquisition Corp Units TDACU Stock Holding History

UBS Group’s Portfolio TDACU Stock Details TDACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$94.3K	Sell	8,338 -1	-0%	-$12	﹤0.01%	7222
2026 Q1	$87.6K	Hold	8,339	–	–	﹤0.01%	7061
2025 Q4	$87.8K	Buy	8,339 +9	+0.1%	+$94	﹤0.01%	6966
2025 Q3	$85.7K	Hold	8,330	–	–	﹤0.01%	7228
2025 Q2	$85.7K	Hold	8,330	–	–	﹤0.01%	7359
2025 Q1	$84.5K	Buy	8,330 +150	+2%	+$1.51K	﹤0.01%	7177
2024 Q4	$82K	Buy	+8,180	New	+$81.9K	﹤0.01%	6994

Other funds holding TDACU

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

UBS Group's TDACU Position: Q2 2026 in Review

UBS Group reduced its Translational Development Acquisition Corp Units (TDACU) stake by 0.01% in Q2 2026, selling an estimated $12 and leaving 8,338 shares worth $94.3K. The position accounts for ﹤0.01% of the portfolio, ranked #7222.

UBS Group first reported a position in TDACU in Q4 2024 and has held it in 7 quarters since. 3 funds tracked by Wall St. Rank hold TDACU as of Q2 2026.

UBS Group held 8,338 shares of Translational Development Acquisition Corp Units worth $94.3K as of Q2 2026.
UBS Group sold 1 Translational Development Acquisition Corp Units share in Q2 2026, an estimated $12.
Translational Development Acquisition Corp Units made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7222 holding.
UBS Group first reported a position in Translational Development Acquisition Corp Units in Q4 2024 and has held it in 7 quarters since.
3 funds tracked by Wall St. Rank held Translational Development Acquisition Corp Units as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.